Wolfe Research Downgrades ResMed to Underperform, Announces $180 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wolfe Research has downgraded ResMed (NYSE:RMD) from Peer Perform to Underperform, setting a price target of $180.

September 18, 2024 | 9:52 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wolfe Research downgraded ResMed to Underperform with a $180 price target, indicating potential downside.
The downgrade from Peer Perform to Underperform by Wolfe Research suggests a negative outlook for ResMed's stock. The $180 price target indicates a potential decrease in stock value, which could lead to a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100